Capecitabine (X) combined with trastuzumab (H) as first-line therapy in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC)

被引：0

作者：

Xu, Ligong ^{[1
]}

Song, Santai ^{[2
]}

Zhu, Jianxin ^{[3
]}

Luo, Rongcheng ^{[4
]}

Li, Lejing ^{[5
]}

Jiao, Shunchang ^{[2
]}

Pan, Hongming ^{[6
]}

Tao, Ming ^{[7
]}

Su, Yongqian ^{[8
,9
]}

Liu, Duanqi

机构：

[1] Fudan Univ, Canc Hosp, Shanghai 200433, Peoples R China

[2] Hosp 307 PLA, Beijing, Peoples R China

[3] Shanghai 2 Med Univ, Ruijin Hosp, Shanghai, Peoples R China

[4] First Mil Med Univ, Nanfang Hosp, Guangzhou, Guangdong, Peoples R China

[5] Heilongjiang Prov Canc Hosp, Haerbin, Peoples R China

[6] Zhejiang Univ, Shao Yifu Hosp, Hangzhou 310003, Zhejiang, Peoples R China

[7] Suzhou Univ, Hosp 1, Suzhou 215006, Peoples R China

[8] Jiangsu Prov Peoples Hosp, Nanjing, Peoples R China

[9] Gen Hosp Beining Mil Area, Beijing, Peoples R China

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：38 / 38

页数：1